Skip to main
LYEL

Lyell Immunopharma (LYEL) Stock Forecast & Price Target

Lyell Immunopharma (LYEL) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lyell Immunopharma, Inc. reported a strong financial position with cash, cash equivalents, and marketable securities increasing to $320 million as of the end of the latest quarter, up from $297 million in the previous quarter, primarily due to a successful private placement. The company is making significant advancements in its pipeline, particularly with the dual-targeting CAR T-cell therapy, rondecabtagene autoleucel, which has established a best-in-class profile, as well as potential opportunities with a novel CAR T-cell candidate for refractory metastatic colorectal cancer. Expert feedback suggests Lyell's existing dataset for LYL273 has surpassed clinical expectations for success in treating advanced colorectal cancer, further strengthening the company's growth prospects in the CAR T-cell therapy market.

Bears say

Lyell Immunopharma experienced a decline in research and development expenses to $28.2 million in the third quarter of 2025, down from $34.9 million in the previous quarter, signifying potential financial constraints in advancing its pipeline. The company faces significant risks, including challenges in growing the CAR-T market for non-Hodgkin lymphoma, potential deterioration in the efficacy of its product candidates, and possible safety concerns that could adversely affect their marketability. Concerns regarding the durability of treatment responses and the management of toxicities further hamper the company's outlook, as existing data does not provide sufficient assurance of its products' effectiveness and safety at scale.

Lyell Immunopharma (LYEL) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lyell Immunopharma (LYEL) Forecast

Analysts have given Lyell Immunopharma (LYEL) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Lyell Immunopharma (LYEL) has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lyell Immunopharma (LYEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.